Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

scientific article

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2010PLoSO...513540E
P356DOI10.1371/JOURNAL.PONE.0013540
P3181OpenCitations bibliographic resource ID336655
P932PMC publication ID2978690
P698PubMed publication ID21085635
P5875ResearchGate publication ID47812924

P50authorFabrizio EnsoliQ55069671
Giovanni PanicciaQ55302856
Stefania BellinoQ55302859
Massimo GalliQ56394582
Gioacchino AngaranoQ56424445
Adriano LazzarinQ56447702
Barbara EnsoliQ21255143
Carlo TortiQ30650659
Nicoletta LadisaQ30650673
Giampiero CarosiQ30650713
Laura SighinolfiQ30650724
Alessandra LatiniQ51846044
Orietta PicconiQ38546631
Stefano RusconiQ40213049
Giuseppe TambussiQ47158634
P2093author name stringEnrico Garaci
Aurelio Cafaro
Vittorio Francavilla
Angela Arancio
Antonella Tripiciano
Arianna Scoglio
Cristina Ariola
Cristina Iori
Cristina Mussini
Donato Scaramuzzi
Fabrizio Soscia
Florio Ghinelli
Francesco Mazzotta
Giovanni Di Perri
Guido Palamara
Maria J Ruiz Alvarez
Massimo Campagna
Massimo Di Pietro
Olimpia Longo
Raffaele Visintini
Roberto Esposito
Simone Marcotullio
Stefano Bonora
Vito S Mercurio
P2860cites workImmune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 PathwayQ63351477
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individualsQ67982548
Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytesQ71396779
Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycleQ73263337
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapyQ73308229
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations ofQ73848661
The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressorsQ82644038
A new subset of human naive CD8+ T cells defined by low expression of IL-7R alpha.Q53545517
Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy.Q54057499
Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy.Q54734214
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemiaQ57075698
Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral TherapyQ57075703
The therapeutic phase I trial of the recombinant native HIV-1 Tat proteinQ57665211
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccineQ59511395
Candidate HIV-1 Tat vaccine development: from basic science to clinical trialsQ59647820
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDSQ61641064
Immune activation and inflammation in HIV-1 infection: causes and consequencesQ22252860
The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT proteinQ24680024
Tat protein induces self-perpetuating permissivity for productive HIV-1 infectionQ24683211
Quantifying the uncertainty in forecasts of anthropogenic climate changeQ28141336
HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic regionQ28252310
Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiationQ28280204
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathologyQ28287124
Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reactionQ28298254
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivationQ28361880
[21] Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reactionQ29544077
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cellsQ29616205
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionQ29619738
Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapyQ30391183
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cellsQ33181641
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversityQ33220546
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cellsQ33250088
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophagesQ33255758
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcomeQ33521702
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strainsQ33785321
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.Q33941997
Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6PQ34055475
Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapyQ34068204
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responsesQ34105993
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodesQ34297394
Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear eventsQ34344850
The survival benefits of AIDS treatment in the United StatesQ34533291
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnoverQ34692601
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatmentQ34937231
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.Q34985945
Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoirQ35155025
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotypeQ35749755
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.Q36379230
HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivoQ36384710
Human macrophages support persistent transcription from unintegrated HIV-1 DNA.Q36511684
Early transcription from nonintegrated DNA in human immunodeficiency virus infectionQ36524970
The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure.Q36632734
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivationQ36639380
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokinesQ36687077
Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.Q36845770
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.Q37178883
Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected childrenQ37194666
Cellular reservoirs of HIV-1 and their role in viral persistenceQ37196089
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyQ37200979
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?Q37220038
Evaluation of an automated instrument for viability and concentration measurements of cryopreserved hematopoietic cells.Q50489286
The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children.Q51047765
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.Q51828622
Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.Q51964201
Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.Q51998598
Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression.Q52192468
Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivoQ37348552
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidityQ37378238
The challenge of finding a cure for HIV infectionQ37407598
Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?Q37493607
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidateQ37661107
Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection.Q37768630
Antiretroviral therapy and management of HIV infectionQ37770721
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individualsQ37771138
The preventive phase I trial with the HIV-1 Tat-based vaccineQ38378021
Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells.Q39443021
Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapyQ39685944
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccinesQ40419534
Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cellsQ40508633
HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activityQ40517749
Regulation of HIV gene expressionQ41119975
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcomaQ41435232
Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line.Q41615187
HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell lineQ41714317
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patientsQ41734588
Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.Q41925734
The independent effect of drug resistance on T cell activation in HIV infectionQ42998780
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconvertersQ43671904
Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesisQ43872292
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).Q43967379
The trans-activator gene of the human T cell lymphotropic virus type III is required for replicationQ44579665
Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infectionQ44674538
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infectionQ45341243
Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South AfricansQ45710857
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infectionQ45732713
HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapyQ45751207
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.Q45761033
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.Q45767659
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particlesQ45887444
Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.Q46077395
Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens.Q46200764
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapyQ47960975
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectimmunizationQ1415366
P304page(s)e13540
P577publication date2010-11-11
P1433published inPLOS OneQ564954
P1476titleTherapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART
P478volume5

Reverse relations

cites work (P2860)
Q46698274"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".
Q37054470A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice
Q44280840A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Q43973641A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies
Q94587776A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy
Q33916162An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge
Q92906228Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease
Q26764851Approaches to preventative and therapeutic HIV vaccines
Q50066811Aptamers in HIV research diagnosis and therapy.
Q36083803Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort
Q27333734Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines
Q89615834Cellular stress responses and dysfunctional Mitochondrial-cellular senescence, and therapeutics in chronic respiratory diseases
Q34148683Challenges in HIV Vaccine Research for Treatment and Prevention
Q42217775Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice.
Q64259098Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study
Q37967232Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).
Q44398270Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Q38533881Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine
Q30364312Developments in HIV-1 immunotherapy and therapeutic vaccination.
Q42061242Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide
Q35354848Expression of the IL-7 receptor alpha-chain is down regulated on the surface of CD4 T-cells by the HIV-1 Tat protein
Q36242915HIV Infects Bronchial Epithelium and Suppresses Components of the Mucociliary Clearance Apparatus
Q35867173HIV RNA suppression and immune restoration: can we do better?
Q36864918HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent v
Q35552889HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial
Q36109585HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology
Q34477471HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies
Q36986644HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial
Q35208314IL-7 receptor recovery on CD8 T-cells isolated from HIV+ patients is inhibited by the HIV Tat protein
Q41468434Identification of a highly conserved surface on Tat variants
Q37104090Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein
Q33739129Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice
Q34145979Interferon-alpha administration enhances CD8+ T cell activation in HIV infection
Q37724091Lessons learned from HIV vaccine clinical efficacy trials
Q58960764Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules
Q37153763Molecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications
Q26777222Mucociliary dysfunction in HIV and smoked substance abuse
Q33603602Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.
Q57095865Natural SIV Infection
Q38692205New challenges in therapeutic vaccines against HIV infection.
Q38212101Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors
Q36605014Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice.
Q92995413TGF-β1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells
Q35040673The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses
Q37364423The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice
Q34756847The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile
Q42253045The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.
Q33864926The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study
Q54217910The role of HIV Tat protein in HIV-related cardiovascular diseases.
Q38013505Therapeutic vaccines against HIV infection
Q83564526Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens
Q36827396tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.

Search more.